Aptose Biosciences Inc. is a clinical-stage biotechnology company focused on developing precision medicines addressing unmet medical needs in oncology, with an initial focus on hematology. The Companyâ€™s lead clinical-stage, oral kinase inhibitor tuspetinib (TUS) has demonstrated activity as a monotherapy and in combination therapy in patients with relapsed or refractory acute myeloid leukemia (AML) and is being developed as a frontline triplet therapy in newly diagnosed AML. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of anti-cancer therapies and regimens without overlapping toxicities. Its Luxeptinib (LUX) is being developed for the treatment of patients with certain B-cell malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and certain non-Hodgkinâ€™s lymphomas (NHL) who are resistant or intolerant to conventional treatments.

Employees

Sector

Pharmaceuticals

More about the company

Market Cap	4.31M 3.79M 3.52M 3.23M 6.07M 415M 6.17M 41.83M 16.34M 204M 16.19M 15.84M 706M	P/E 2024	-0.19x	P/E 2025	-0.15x
Enterprise Value	30.59M 26.87M 24.98M 22.93M 43.08M 2.95B 43.74M 297M 116M 1.45B 115M 112M 5.01B	EV / Sales 2024	-	EV / Sales 2025	-
Free-Float	72.64%	Yield 2024 *	-	Yield 2025	-

07-02	Hanmi Pharmaceutical Closes Acquisition of Aptose Biosciences	MT
06-29	Hanmi Pharm. Co., Ltd. completed the acquisition of remaining 80.07% stake in Aptose Biosciences Inc..	CI
06-15	Aptose Biosciences Inc. Presents Safety, Response and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML	CI
06-15	Aptose Biosciences Updated Tuscany Trial Data Reported in Oral Presentation at EHA 2026	MT
05-29	Aptose Biosciences Says Acquisition by Hanmi Delayed Until June	MT
05-29	Aptose Biosciences says closing of arrangement with Hanmi Pharmaceutical further delayed	RE
05-13	Aptose Biosciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
03-31	Aptose Shareholders Approve Acquisition By Hanmi Pharmaceutical in "Go Private" Transaction	MT
03-31	Aptose Biosciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-31	Aptose Biosciences Inc. - Shareholder/Analyst Call
03-30	Aptose Biosciences Inc. Auditor Raises 'Going Concern' Doubt	CI
03-23	Leading independent proxy advisory firm Glass Lewis endorses Aptose plan of arrangement	RE
03-23	Aptose Biosciences Brief: Independent Proxy Advisory Firm Glass Lewis Endorses Aptose Plan of Arrangement With Hanmi Pharmaceutical	MT

03-19	Leading independent proxy advisory firm ISS recommends Aptose Biosciences shareholders vote "for" proposed plan of arrangement with Hanmi Pharmaceutical	RE
03-19	Aptose Brief: Independent Proxy Advisory Firm ISS Recommends Aptose Shareholders Vote "FOR" Proposed Plan of Arrangement with Hanmi Pharmaceutical	MT
11/06/24	HC Wainwright Adjusts Price Target on Aptose Biosciences to $7 From $23, Maintains Buy Rating	MT
10/11/23	RBC Cuts Price Target on Aptose Biosciences to $18 From $23, Keeps Outperform, Speculative Risk	MT
11/08/23	Oppenheimer Adjusts Aptose Biosciences Price Target to $15 From $50, Maintains Outperform Rating	MT

07-01	Aptose Biosciences Announces Completion of Acquisition by Hanmi Pharmaceutical	AQ
06-15	Aptose Biosciences : Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2026 EHA Congress in Oral Presentation	PU
06-15	Aptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2026 EHA Congress in Oral Presentation	AQ
05-29	Aptose Biosciences Announces Update on Anticipated Timing of Closing of the Plan of Arrangement with Hanmi Pharmaceutical	AQ
05-13	Aptose Biosciences: Q1 Earnings Snapshot	AQ

12-05	Tokenización: ¿Va a cambiar tanto la vida de los inversores?
12-05	Universo cripto: la tokenizzazione cambierà davvero la vita degli investitori?
09/09/23	Vastzetting: Ethereum scheert hoge toppen - cryptonieuws
08/09/23	Staking: Ethereum raggiunge nuove vette - Resoconto Cripto

Aptose Biosciences Share Price Nasdaq

Stocks

Pharmaceuticals

Valuation: Aptose Biosciences

Latest news : Aptose Biosciences

Last Transcript: Aptose Biosciences

Analysts' recommendations: Aptose Biosciences

Press Releases: Aptose Biosciences

News in other languages: Aptose Biosciences

Quotes and Performance

Managers and Directors: Aptose Biosciences

Other Pharmaceuticals

Financials

Company Profile

Manager	Title	Age	Since
C. Payne DFI	Director of Finance/CFO	63	26/06/2022
Victor Montalvo-Lugo CTO	Chief Tech/Sci/R&D Officer	-	31/10/2019
Rafael Bejar CTO	Chief Tech/Sci/R&D Officer	54	31/12/2019

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
APTOSE BIOSCIENCES	-7.92%	+21.79%	-	-	4.32M
ELI LILLY AND COMPANY	+0.86%	+1.43%	+47.17%	+161.40%	1,067B
JOHNSON & JOHNSON	+1.59%	+4.09%	+56.51%	+52.79%	635B
ABBVIE INC.	+0.95%	+1.91%	+36.30%	+83.13%	458B
ROCHE HOLDING AG	+1.60%	+6.25%	+37.00%	+30.00%	347B
NOVARTIS AG	-0.60%	+1.52%	+36.67%	+39.80%	295B
ASTRAZENECA PLC	-0.14%	+0.60%	+17.29%	+18.19%	262B
NOVO NORDISK A/S	+0.09%	-2.82%	-29.09%	-41.29%	216B
AMGEN INC.	+1.22%	+2.66%	+22.66%	+59.81%	203B
GILEAD SCIENCES, INC.	-1.18%	-3.70%	+11.28%	+67.43%	161B
Average	-0.35%	+1.33%	+26.20%	+52.36%	404.83B
Weighted average by Cap.	+0.76%	+1.95%	+35.99%	+78.15%

	2024	2025
Net sales	-	-
Net income	-25.43M -22.34M -20.77M -19.06M -35.81M -2.45B -36.36M -247M -96.36M -1.2B -95.46M -93.41M -4.16B	-25.47M -22.37M -20.8M -19.09M -35.87M -2.45B -36.42M -247M -96.51M -1.21B -95.61M -93.55M -4.17B
Net Debt	4.49M 3.94M 3.66M 3.36M 6.32M 432M 6.42M 43.52M 17M 212M 16.84M 16.48M 735M	26.28M 23.08M 21.46M 19.69M 37M 2.53B 37.57M 255M 99.57M 1.24B 98.64M 96.51M 4.3B